Showing session: reset
Novel Targets
- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies
Esteban Cvitkovic
Oncoethix SA, Lausanne, Switzerland
- Free
- Coming soon
- Some slides withheld
Discussant
James E. Bradner
Dana-Farber Cancer Inst., Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer
Amita Patnaik
South Texas Accelerated Research Therapeutics (START), San Antonio, TX, United States
- Free
- audio + slides
- Some slides withheld
Discussant
Gary K. Schwartz
Columbia Univ. Irving Comp. Cancer Ctr., New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
A first-in-human phase I study of the safety and pharmacokinetic (PK) activity of DEDN6526A, an anti-endothelin B receptor (ETBR) antibody-drug conjugate (ADC), in patients with metastatic or unresectable melanoma
Jeffrey R Infante
Sarah Cannon Research Institute, Nashville, TN, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Steven J. O'Day
Beverly Hills Cancer Center, Beverly Hills, CA, United States
- Free
- slides video
- audio + slides
- All slides included
Dabrafenib stimulates radioiodine uptake in BRAF V600E mutant advanced papillary thyroid cancer
Stephen M Rothenberg
Massachusetts General Hosp. Cancer Ctr., Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Richard M. Marais
Cancer Research UK Manchester Institute, Manchester, United Kingdom